Sanofi India Ltd
Sanofi India Ltd (SANOFI) last reported results for the quarter ended Dec 2024, with sales of ₹515 crore and net profit of ₹91 crore. The stock last traded at ₹2,945, a market capitalisation of ₹6,779 crore, on a P/E of 15.3. Over the past 52 weeks the stock has ranged between ₹2,914 and ₹4,898. Figures are as of 9 Oct 2026 and are not real time.
Sanofi India Ltd share price and key metrics
- Current price
- ₹2,945
- Market cap
- ₹6,779 cr
- Stock P/E
- 15.3
- Book value
- ₹374
- ROE
- 47.1%
- ROCE
- 49.2%
- Dividend yield
- 2.55%
- 52w high / low
- 4898/2914
Metrics as of 9 Oct 2026. Not real time.
Track Sanofi India Ltd
Cruxal reads every Sanofi India Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Sanofi India Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 1%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -25%
- 10 Years
- 1%
- 5 Years
- -10%
- 3 Years
- -13%
- 1 Year
- -38%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 47%
Sanofi India Ltd quarterly results
In the quarter ended Dec 2024, sales were ₹515 cr, up 9.8% from ₹469 cr a year earlier. Net profit was ₹91 cr, down 34.1% year on year.
| ₹ crore | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|
| Sales | 515 | 491 | 469 | 511 | 464 | 524 | 515 |
| Expenses | 393 | 377 | 370 | 374 | 348 | 404 | 397 |
| Operating profit | 122 | 114 | 100 | 137 | 116 | 120 | 118 |
| OPM % | 24% | 23% | 21% | 27% | 25% | 23% | 23% |
| Other income | 57 | 82 | 77 | 41 | 21 | 2 | 14 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 9 | 9 | 9 | 9 | 9 | 10 |
| Profit before tax | 169 | 186 | 167 | 169 | 127 | 113 | 122 |
| Tax % | 27% | 18% | 18% | 19% | 19% | 27% | 25% |
| Net profit | 123 | 152 | 138 | 137 | 103 | 82 | 91 |
| EPS (₹) | 53.43 | 66.04 | 59.87 | 59.39 | 44.87 | 35.74 | 39.70 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sanofi India Ltd annual results
| ₹ crore | Dec 2023 | Dec 2024 |
|---|---|---|
| Sales | 1,996 | 2,013 |
| Operating profit | 488 | 491 |
| OPM % | 24% | 24% |
| Net profit | 603 | 413 |
| EPS (₹) | 262.13 | 179.70 |
TTM is the trailing twelve months to the most recent quarter.
Sanofi India Ltd balance sheet
| ₹ crore | Dec 2023 | Dec 2024 |
|---|---|---|
| Equity capital | 23 | 23 |
| Reserves | 992 | 838 |
| Borrowings | 19 | 19 |
| Other liabilities | 681 | 732 |
| Total liabilities | 1,715 | 1,612 |
| Fixed assets | 315 | 312 |
| CWIP | 16 | 18 |
| Investments | 0 | 0 |
| Other assets | 1,384 | 1,281 |
| Total assets | 1,715 | 1,612 |
As reported by the company. Total assets equal total liabilities by construction.
Sanofi India Ltd cash flow
| ₹ crore | Dec 2023 | Dec 2024 |
|---|---|---|
| Cash from operations | 230 | 462 |
| Cash from investing | 38 | -180 |
| Cash from financing | -878 | -392 |
| Net cash flow | -610 | -111 |
| Free cash flow | 220 | 426 |
| CFO / operating profit | 97% | 114% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Sanofi India Ltd operating ratios
| Per year | Dec 2023 | Dec 2024 |
|---|---|---|
| ROCE % | — | 49% |
| Debtor days | 24 | 42 |
| Inventory days | 254 | 186 |
| Days payable | 112 | 151 |
| Cash conversion cycle | 167 | 77 |
| Working capital days | 35 | 20 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Sanofi India Ltd shareholding pattern
Promoters held 60.40% at Jun 2026, broadly unchanged since Jun 2025. FIIs 5.69% and DIIs 19.87%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% | 60.40% |
| FIIs | 5.78% | 5.64% | 5.58% | 5.61% | 5.57% | 5.55% | 5.65% | 5.69% |
| DIIs | 22.62% | 22.94% | 23.02% | 23.06% | 22.28% | 21.30% | 21.12% | 19.87% |
| Public | 11.20% | 11.04% | 11.01% | 10.94% | 11.75% | 12.75% | 12.84% | 14.05% |
| No. of shareholders | 66,211 | 66,401 | 68,196 | 66,790 | 71,395 | 75,813 | 75,758 | 80,005 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Sanofi India Ltd corporate filings
- Kindly refer the attachment.Company Updatelow impact
- SEBI Filing Reveals Inter-se Transfer of 15.20% Stake by Promoter Group of Sanofi India, Exempted Under Regulation 10(1)(a)(iii)Insider Trading / SASTmedium impact
Cruxal's analysis: Sanofi India’s promoter group, through Sanofi Healthcare India Private Limited, has…
Read the full analysis - Sanofi India Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Sanofi India Limited: Promoter group executes inter-se transfer of 15.20% stake at INR 3,052 per shareInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of 35 lakh equity shares…
Read the full analysis - Sanofi India receives disclosure of promoter group share transaction under PIT RegulationsCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd received a disclosure on September 25, 2026, from Sanofi Healthcare…
Read the full analysis - Sanofi India receives promoter disclosure from Hoechst GmbH under SEBI PIT RegulationsCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd received a disclosure on September 25, 2026, from its promoter, Hoechst…
Read the full analysis - Sanofi India Ltd: Routine regulatory disclosure under SEBI LODR Regulation 30Company Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Sanofi India Limited: Internal Promoter Reorganization via Inter-se Transfer of 35 Lakh SharesInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of 35 lakh equity shares…
Read the full analysis - Sanofi India Limited: Internal Promoter Group Reorganization via 35 lakh Share Block DealInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of 35 lakh equity shares…
Read the full analysis - Sanofi India Limited: Internal Promoter Group Reorganization via 15.20% Stake TransferInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of 35 lakh equity shares…
Read the full analysis - Sanofi India Limited: Promoter Group Executes Inter-se Transfer of 35 Lakh SharesInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of 35 lakh equity shares…
Read the full analysis - Kindly refer the attachment.Insider Trading / SASTlow impact
- Sanofi India Ltd: Routine Regulatory Disclosure Under Regulation 30Company Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Sanofi India Limited announces inter-se promoter transfer of 35 lakh equity sharesInsider Trading / SASTlow impact
Cruxal's analysis: Sanofi India Limited has disclosed an inter-se transfer of up to 35 lakh equity shares…
Read the full analysis - Sanofi India Ltd: Routine Regulatory Disclosure Under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Sanofi India Ltd receives Show Cause Notice from GST authoritiesCompany Updatelow impact
Cruxal's analysis: Sanofi India has disclosed the receipt of a Show Cause Notice (SCN) from GST authorities…
Read the full analysis - Sanofi India Ltd: Routine Regulatory Disclosure under SEBI LODRCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Sanofi India Ltd: Routine Regulatory Disclosure Under Regulation 30Company Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed a routine disclosure under Regulation 30 of the SEBI (LODR)…
Read the full analysis - Sanofi India reports strong Q2 2026 diabetes segment growth and margin expansion, offsetting export headwindsCompany Updatehigh impact
Cruxal's analysis: Sanofi India Limited reported a strong second quarter for 2026, highlighted by a 14%…
Read the full analysis - Sanofi India Ltd announces outcome of analyst/investor meetingCompany Updatelow impact
Cruxal's analysis: Sanofi India Ltd has filed the outcome of its analyst/investor meeting held on August 6…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.